Thyroid CancerTHY-CANCNCT05752604
Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer
An observational study of Thyroid Cancer, run by Istituto Auxologico Italiano at 1 site in Italy.
Trial summary
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Thyroid Cancer
- How many people
- 3,000 participants
- Where
- 1 siteItaly
- Study dates
- 12 Jul 2022to 8 Mar 2042
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: all consecutive patients referred to our tertiary clinical center for thyroid cancer
Who may be able to join
- thyroid cancer diagnosis
Who cannot join
- patients unable to sign informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Istituto Auxologico Italiano, IRCCS
Milan, 20149
Laura Fugazzola, MD, +3902619112727, l.fugazzola@auxologico.it
About this study
Official title: Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.
- Conditions
- Thyroid Cancer
- Medical subject headings
- Thyroid Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Dynamic risk stratification
impact of the different variables on the DRS
Measured: one year from the primary treatment
Dynamic risk stratification
impact of the different variables on the DRS
Measured: five years from the primary treatment
Dynamic risk stratification
impact of the different variables on the DRS
Measured: ten years from the primary treatment
Progression-free survival
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Measured: one year from the primary treatment
Progression-free survival
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Measured: five years from the primary treatment
Progression-free survival
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Measured: ten years from the primary treatment
Overall survival
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
Measured: one year from the primary treatment
Overall survival
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
Measured: five years from the primary treatment
Overall survival
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
Measured: ten years from the primary treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2023
- Study start12 Jul 2022
- Primary completion8 Mar 2032 (estimated)
- Study completion8 Mar 2042 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid CancerStudies of the same condition, open and under way.
- More trials run by Istituto Auxologico ItalianoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istituto Auxologico Italiano
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05752604
- Sponsor's protocol ID
- 05C212
- Acronym
- THY-CANC
- Status last verified
- Aug 2025
- First submitted
- 17 Feb 2023
- Last updated
- 3 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer
- ClinicalTrials.gov ID
- NCT05752604
- Acronym / sponsor ID
- THY-CANC / 05C212
- Conditions
- Thyroid Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Istituto Auxologico ItalianoUniversity, hospital or other
- Study start
- 12 Jul 2022 (actual)
- Primary completion
- 8 Mar 2032 (estimated)
- Study completion
- 8 Mar 2042 (estimated)
- First posted
- 2 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- all consecutive patients referred to our tertiary clinical center for thyroid cancer
Key inclusion criteria (1 listed)
- thyroid cancer diagnosis
Key exclusion criteria (1 listed)
- patients unable to sign informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Dynamic risk stratification
Time frame: one year from the primary treatment
impact of the different variables on the DRS
Dynamic risk stratification
Time frame: five years from the primary treatment
impact of the different variables on the DRS
Dynamic risk stratification
Time frame: ten years from the primary treatment
impact of the different variables on the DRS
Progression-free survival
Time frame: one year from the primary treatment
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Progression-free survival
Time frame: five years from the primary treatment
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Progression-free survival
Time frame: ten years from the primary treatment
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Overall survival
Time frame: one year from the primary treatment
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
Overall survival
Time frame: five years from the primary treatment
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
Overall survival
Time frame: ten years from the primary treatment
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2025.
Related trials for Thyroid Cancer
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingObservational study
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Pleuropulmonary Blastoma, Cystic Nephroma
Recruiting
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Thyroid Gland Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Cancer, run by Istituto Auxologico Italiano at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Laura Fugazzola, MD (+390261911 ext. 2727, l.fugazzola@auxologico.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dynamic risk stratification (time frame: one year from the primary treatment). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2025.